Influence of cyclooxygenase inhibitors on gut immune cell distribution and apoptosis rate in experimental sepsis.
The aim of this study was to determine if cyclooxygenase (COX) inhibitors influence immune cell distribution in the small intestinal mucosa and mesenteric lymph nodes (MLNs), the grade of mucosal damage, and the rate of apoptosis in septic rats. The effects induced by a selective COX-2 inhibitor (SC-236) were compared with those of a nonselective COX-1 and -2 inhibitor (indomethacin). Cecal ligation and puncture (CLP), CLP + SC-236 p.o, and CLP + indomethacin p.o, were evaluated. Animals were harvested 6 and 24 h after CLP, respectively. The concentration of proinflammatory cytokines was higher in ascitic fluid than in blood. CLP + SC-236 attenuated IL-6 in plasma and in ascitic fluid and CLP + indomethacin augmented TNF-alpha in ascitic fluid compared with CLP at 6 h. CLP + SC-236 gave a lesser degree of mucosal damage compared with CLP alone or with indomethacin at 6 and 24 h (P < 0.05). Untreated CLP had significant reductions in the number of T lymphocytes in the villi and increases of macrophages in the mucosa and MLNs compared with controls (P < 0.05). CLP + indomethacin decreased T lymphocytes in the villi and MLNs. CLP caused an enhanced apoptosis in the mucosa compared with controls (P < 0.05), pretreatment with COX inhibitors did not significantly change this. Both COX inhibitors enhanced apoptosis in MLNs and attenuated the increase of macrophages in mucosa and MLNs (P < 0.05). It is proposed that the increased apoptosis and the decrease in T cells in the mucosa may be causally related. Apoptosis of lymphocytes may impair the immunologic defense in sepsis. Furthermore, loss of intestinal epithelial cells may compromise bowel wall integrity and facilitate translocation.
Osterberg
Johanna
J
Department of Surgery, University Hospital, Uppsala, Sweden. johanna.osterberg@ltdalarna.se
Ljungdahl
Mikael
M
Haglund
Ulf
U
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D051545:Cyclooxygenase 1 / Q000276:immunology; D051546:Cyclooxygenase 2 / Q000276:immunology; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D004195:Disease Models, Animal; D018928:Immunity, Mucosal / Q000187:drug effects*; D007213:Indomethacin / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000276:immunology; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D007421:Intestine, Small / Q000276:immunology / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D008643:Mesentery / Q000276:immunology / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D013449:Sulfonamides / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D000096926:Benzenesulfonamides
D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D016861:Cyclooxygenase Inhibitors; D007213:Indomethacin; D015850:Interleukin-6; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; C119130:4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; D000096926:Benzenesulfonamides; C496513:Ptgs1 protein, rat; C489691:Ptgs2 protein, rat